CA2505445A1 - Composition a base de liposomes fusogenes et procede correspondant - Google Patents

Composition a base de liposomes fusogenes et procede correspondant Download PDF

Info

Publication number: CA2505445A1
Authority: CA; Canada
Prior art keywords: liposomes; lipid; liposome; compound; peg
Prior art date: 1996-10-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002505445A

Other languages

English (en)

Inventor

Francis J. Martin

Samuel Zalipsky

Paul S. Uster

Theresa M. Allen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alza Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-11

Filing date

1997-10-10

Publication date

1998-04-23

1997-10-10 Application filed by Individual filed Critical Individual

1997-10-10 Priority claimed from CA002267904A external-priority patent/CA2267904C/fr

1998-04-23 Publication of CA2505445A1 publication Critical patent/CA2505445A1/fr

Status Abandoned legal-status Critical Current

Links

239000002502 liposome Substances 0.000 title claims abstract description 251
239000000203 mixture Substances 0.000 title claims abstract description 70
238000000034 method Methods 0.000 title claims abstract description 55
230000000799 fusogenic effect Effects 0.000 title abstract description 32
210000004027 cell Anatomy 0.000 claims abstract description 130
150000001875 compounds Chemical class 0.000 claims abstract description 103
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 70
150000002632 lipids Chemical class 0.000 claims description 150
229920001223 polyethylene glycol Polymers 0.000 claims description 71
239000003446 ligand Substances 0.000 claims description 41
229920000642 polymer Polymers 0.000 claims description 37
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 34
108090000623 proteins and genes Proteins 0.000 claims description 29
-1 polymethyloxazoline Polymers 0.000 claims description 27
230000002209 hydrophobic effect Effects 0.000 claims description 24
102000005962 receptors Human genes 0.000 claims description 23
108020003175 receptors Proteins 0.000 claims description 23
239000000725 suspension Substances 0.000 claims description 23
239000003795 chemical substances by application Substances 0.000 claims description 22
239000003814 drug Substances 0.000 claims description 21
230000008685 targeting Effects 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
235000019152 folic acid Nutrition 0.000 claims description 18
239000011724 folic acid Substances 0.000 claims description 18
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 14
229960000304 folic acid Drugs 0.000 claims description 14
239000002202 Polyethylene glycol Substances 0.000 claims description 13
230000001225 therapeutic effect Effects 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 12
229940124597 therapeutic agent Drugs 0.000 claims description 12
239000000693 micelle Substances 0.000 claims description 9
108091034117 Oligonucleotide Proteins 0.000 claims description 7
108010024212 E-Selectin Proteins 0.000 claims description 6
102000006815 folate receptor Human genes 0.000 claims description 5
108020005243 folate receptor Proteins 0.000 claims description 5
NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 4
239000012634 fragment Substances 0.000 claims description 4
238000003780 insertion Methods 0.000 claims description 4
230000037431 insertion Effects 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 4
239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 4
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
239000002246 antineoplastic agent Substances 0.000 claims description 3
229920006187 aquazol Polymers 0.000 claims description 3
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 3
102000006495 integrins Human genes 0.000 claims description 3
108010044426 integrins Proteins 0.000 claims description 3
229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims description 3
108091033319 polynucleotide Proteins 0.000 claims description 3
102000040430 polynucleotide Human genes 0.000 claims description 3
239000002157 polynucleotide Substances 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
108010041397 CD4 Antigens Proteins 0.000 claims description 2
108010067306 Fibronectins Proteins 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
108010092694 L-Selectin Proteins 0.000 claims description 2
210000001744 T-lymphocyte Anatomy 0.000 claims description 2
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 2
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
229940088594 vitamin Drugs 0.000 claims description 2
229930003231 vitamin Natural products 0.000 claims description 2
235000013343 vitamin Nutrition 0.000 claims description 2
239000011782 vitamin Substances 0.000 claims description 2
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 claims 2
102000007592 Apolipoproteins Human genes 0.000 claims 1
108010071619 Apolipoproteins Proteins 0.000 claims 1
101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 claims 1
102000009410 Chemokine receptor Human genes 0.000 claims 1
108050000299 Chemokine receptor Proteins 0.000 claims 1
102000019034 Chemokines Human genes 0.000 claims 1
108010012236 Chemokines Proteins 0.000 claims 1
102000001301 EGF receptor Human genes 0.000 claims 1
108060006698 EGF receptor Proteins 0.000 claims 1
101800003838 Epidermal growth factor Proteins 0.000 claims 1
102100037362 Fibronectin Human genes 0.000 claims 1
108060003393 Granulin Proteins 0.000 claims 1
102000009465 Growth Factor Receptors Human genes 0.000 claims 1
108010009202 Growth Factor Receptors Proteins 0.000 claims 1
102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
102100033467 L-selectin Human genes 0.000 claims 1
102000004264 Osteopontin Human genes 0.000 claims 1
108010081689 Osteopontin Proteins 0.000 claims 1
108010035766 P-Selectin Proteins 0.000 claims 1
102100033237 Pro-epidermal growth factor Human genes 0.000 claims 1
102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
102000004338 Transferrin Human genes 0.000 claims 1
108090000901 Transferrin Proteins 0.000 claims 1
108091008605 VEGF receptors Proteins 0.000 claims 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 claims 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims 1
229940116977 epidermal growth factor Drugs 0.000 claims 1
229930182830 galactose Natural products 0.000 claims 1
210000002540 macrophage Anatomy 0.000 claims 1
229960001327 pyridoxal phosphate Drugs 0.000 claims 1
239000012581 transferrin Substances 0.000 claims 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 1
239000011248 coating agent Substances 0.000 abstract description 39
238000000576 coating method Methods 0.000 abstract description 39
229920001600 hydrophobic polymer Polymers 0.000 abstract description 39
230000004927 fusion Effects 0.000 abstract description 29
210000000170 cell membrane Anatomy 0.000 abstract description 15
230000003993 interaction Effects 0.000 abstract description 8
210000000805 cytoplasm Anatomy 0.000 abstract description 3
238000002360 preparation method Methods 0.000 description 48
229920001451 polypropylene glycol Polymers 0.000 description 44
239000000047 product Substances 0.000 description 33
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 32
238000006243 chemical reaction Methods 0.000 description 30
239000012528 membrane Substances 0.000 description 30
239000000243 solution Substances 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
229920001400 block copolymer Polymers 0.000 description 23
239000013612 plasmid Substances 0.000 description 22
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 20
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
206010028980 Neoplasm Diseases 0.000 description 18
125000002091 cationic group Chemical group 0.000 description 17
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
229920000359 diblock copolymer Polymers 0.000 description 16
239000002904 solvent Substances 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 14
238000009472 formulation Methods 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
210000003743 erythrocyte Anatomy 0.000 description 13
238000002835 absorbance Methods 0.000 description 12
239000003638 chemical reducing agent Substances 0.000 description 12
239000012071 phase Substances 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
101150065749 Churc1 gene Proteins 0.000 description 11
239000000126 substance Substances 0.000 description 11
238000005481 NMR spectroscopy Methods 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
102000039446 nucleic acids Human genes 0.000 description 10
108020004707 nucleic acids Proteins 0.000 description 10
150000007523 nucleic acids Chemical class 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 9
239000000232 Lipid Bilayer Substances 0.000 description 9
102100038239 Protein Churchill Human genes 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 9
230000000694 effects Effects 0.000 description 9
210000003617 erythrocyte membrane Anatomy 0.000 description 9
150000008104 phosphatidylethanolamines Chemical class 0.000 description 9
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 8
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
235000012000 cholesterol Nutrition 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
229920001427 mPEG Polymers 0.000 description 8
239000002245 particle Substances 0.000 description 8
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 8
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
108060001084 Luciferase Proteins 0.000 description 7
239000005089 Luciferase Substances 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
239000008186 active pharmaceutical agent Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
229960002433 cysteine Drugs 0.000 description 7
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
235000018417 cysteine Nutrition 0.000 description 7
239000010408 film Substances 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
229960003581 pyridoxal Drugs 0.000 description 7
235000008164 pyridoxal Nutrition 0.000 description 7
239000011674 pyridoxal Substances 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000004721 Polyphenylene oxide Substances 0.000 description 6
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000017531 blood circulation Effects 0.000 description 6
238000003776 cleavage reaction Methods 0.000 description 6
238000010168 coupling process Methods 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
238000009826 distribution Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
230000007017 scission Effects 0.000 description 6
229940063673 spermidine Drugs 0.000 description 6
229920000428 triblock copolymer Polymers 0.000 description 6
102100023471 E-selectin Human genes 0.000 description 5
108010024636 Glutathione Proteins 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
239000004743 Polypropylene Substances 0.000 description 5
230000006037 cell lysis Effects 0.000 description 5
238000004440 column chromatography Methods 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000003511 endothelial effect Effects 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
229960003180 glutathione Drugs 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
150000003904 phospholipids Chemical class 0.000 description 5
230000001737 promoting effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
230000007704 transition Effects 0.000 description 5
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 4
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
206010018910 Haemolysis Diseases 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
238000013459 approach Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
229940072107 ascorbate Drugs 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
230000027455 binding Effects 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
229940014144 folate Drugs 0.000 description 4
239000008103 glucose Substances 0.000 description 4
235000003969 glutathione Nutrition 0.000 description 4
230000008588 hemolysis Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 4
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
239000004417 polycarbonate Substances 0.000 description 4
229920000515 polycarbonate Polymers 0.000 description 4
229920006380 polyphenylene oxide Polymers 0.000 description 4
239000011148 porous material Substances 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
238000010186 staining Methods 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
150000003573 thiols Chemical class 0.000 description 4
FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 3
KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 3
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
102000055025 Adenosine deaminases Human genes 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003012 bilayer membrane Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
150000001793 charged compounds Chemical class 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
230000008878 coupling Effects 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
239000000032 diagnostic agent Substances 0.000 description 3
229940039227 diagnostic agent Drugs 0.000 description 3
UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 3
MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 3
230000008034 disappearance Effects 0.000 description 3
230000012202 endocytosis Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000001125 extrusion Methods 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000001294 propane Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
238000000638 solvent extraction Methods 0.000 description 3
238000000527 sonication Methods 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000007858 starting material Substances 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
239000010409 thin film Substances 0.000 description 3
238000007079 thiolysis reaction Methods 0.000 description 3
FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 2
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 2
YCLSOMLVSHPPFV-UHFFFAOYSA-N 3-(2-carboxyethyldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSCCC(O)=O YCLSOMLVSHPPFV-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
0 B=*(CC(F)(F)F)*C Chemical compound B=*(CC(F)(F)F)*C 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
241000872931 Myoporum sandwicense Species 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930182558 Sterol Natural products 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000001687 destabilization Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
238000002296 dynamic light scattering Methods 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
230000000887 hydrating effect Effects 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000010354 integration Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 2
210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
229920002492 poly(sulfone) Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
238000004513 sizing Methods 0.000 description 2
NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
238000000935 solvent evaporation Methods 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
150000003432 sterols Chemical class 0.000 description 2
235000003702 sterols Nutrition 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
230000014616 translation Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000007794 visualization technique Methods 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
QUGODPAQMQMGRN-UHFFFAOYSA-N (2,3-dinitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O QUGODPAQMQMGRN-UHFFFAOYSA-N 0.000 description 1
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical group CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
MSACGCINQCCHBD-UHFFFAOYSA-N 2,4-dioxo-4-(4-piperidin-1-ylphenyl)butanoic acid Chemical compound C1=CC(C(=O)CC(=O)C(=O)O)=CC=C1N1CCCCC1 MSACGCINQCCHBD-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 1
FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
240000005020 Acaciella glauca Species 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101710081722 Antitrypsin Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
108010061299 CXCR4 Receptors Proteins 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102100031635 Cytoplasmic dynein 1 heavy chain 1 Human genes 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
101000866326 Homo sapiens Cytoplasmic dynein 1 heavy chain 1 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000016551 L-selectin Human genes 0.000 description 1
102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108700018273 Rad30 Proteins 0.000 description 1
101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 1
108700025701 Retinoblastoma Genes Proteins 0.000 description 1
241000271569 Rhea Species 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241001441550 Zeiformes Species 0.000 description 1
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
230000009056 active transport Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000000823 artificial membrane Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
238000011393 cytotoxic chemotherapy Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
238000003795 desorption Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000001159 endocytotic effect Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
229960004413 flucytosine Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
150000004676 glycans Polymers 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000005660 hydrophilic surface Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
OAOSXODRWGDDCV-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine;4-methylbenzenesulfonic acid Chemical compound CN(C)C1=CC=NC=C1.CC1=CC=C(S(O)(=O)=O)C=C1 OAOSXODRWGDDCV-UHFFFAOYSA-N 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
108700025694 p53 Genes Proteins 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
230000009057 passive transport Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
235000008151 pyridoxamine Nutrition 0.000 description 1
239000011699 pyridoxamine Substances 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
235000003499 redwood Nutrition 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
GWIKYPMLNBTJHR-UHFFFAOYSA-M thiosulfonate group Chemical group S(=S)(=O)[O-] GWIKYPMLNBTJHR-UHFFFAOYSA-M 0.000 description 1
238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000011800 void material Substances 0.000 description 1
CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

CA002505445A 1996-10-11 1997-10-10 Composition a base de liposomes fusogenes et procede correspondant Abandoned CA2505445A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2826996P	1996-10-11	1996-10-11
US60/028,269		1996-10-11
CA002267904A CA2267904C (fr)	1996-10-11	1997-10-10	Composition a base de liposomes fusogenes et procede correspondant

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002267904A Division CA2267904C (fr)	1996-10-11	1997-10-10	Composition a base de liposomes fusogenes et procede correspondant

Publications (1)

Publication Number	Publication Date
CA2505445A1 true CA2505445A1 (fr)	1998-04-23

Family

ID=34827906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002505445A Abandoned CA2505445A1 (fr)	1996-10-11	1997-10-10	Composition a base de liposomes fusogenes et procede correspondant

Country Status (1)

Country	Link
CA (1)	CA2505445A1 (fr)

1997
- 1997-10-10 CA CA002505445A patent/CA2505445A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2005-05-20	EEER	Examination request
2009-10-13	FZDE	Dead

Publication	Publication Date	Title
CA2267904C (fr)	2005-08-02	Composition a base de liposomes fusogenes et procede correspondant
US6936272B2 (en)	2005-08-30	10139483Therapeutic liposome composition and method of preparation
US6224903B1 (en)	2001-05-01	Polymer-lipid conjugate for fusion of target membranes
US6043094A (en)	2000-03-28	Therapeutic liposome composition and method
US5620689A (en)	1997-04-15	Liposomes for treatment of B-cell and T-cell disorders
AU2002305094C1 (en)	2002-10-08	Liposome composition for improved intracellular delivery of a therapeutic agent
Klibanov et al.	1990	Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
US7060291B1 (en)	2006-06-13	Modular targeted liposomal delivery system
JP2003535832A (ja)	2003-12-02	ポリヌクレオチドおよび薬物の標的化リポソームへのカプセル化
AU2002305094A1 (en)	2003-03-27	Liposome composition for improved intracellular delivery of a therapeutic agent
US7741431B2 (en)	2010-06-22	Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
EP1231895B1 (fr)	2009-01-07	Systeme modulaire cible d'apport de liposomes
US20040213835A1 (en)	2004-10-28	Method to reduce liposome-induced complement activation
Huang et al.	2016	Bioresponsive liposomes and their use for macromolecular delivery
EP1214935A2 (fr)	2002-06-19	Composition de liposomes fusogènes et procédé correspondant
US20030147944A1 (en)	2003-08-07	Lipid carrier compositions with protected surface reactive functions
AU736055B2 (en)	2001-07-26	Fusogenic liposome composition and method
AU761204B2 (en)	2003-05-29	Fusogenic liposome composition and method
CA2505445A1 (fr)	1998-04-23	Composition a base de liposomes fusogenes et procede correspondant
MXPA99003336A (en)	2000-06-01	Fusogenic liposome composition and method
EP0555317A1 (fr)	1993-08-18	Vehicule d'analogue phospholipidique.
El-Aneed	2003	The feasibility of coating cationic liposomes with malaria circumsporozoite (CS) region II+ peptide for hepatocyte selective targeting
MURCIA UNIV (SPAIN)	1991	International Workshop on Membrane Biotechnology and Membrane Biomaterials (4th) Held in La Manga, Murcia, Spain on 29 May-2 June 1991.